One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN. Our panel of services also include high-quality WRN protein production and established X-ray crystallography protocols.
Werner Syndrome Helicase Platform
Related Content
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
VIEW RESOURCEIntroduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCE